HALO vs JNJ
HALO: Halozyme is a biopharmaceutical company that licenses its proprietary drug-delivery technology to help pharmaceutical partners convert intravenous treatments into more convenient subcutaneous injections. JNJ: Johnson & Johnson is a global leader in innovative pharmaceuticals and advanced medical technology dedicated to addressing the world's most complex health challenges.
Side-by-side fundamentals
| Metric | HALO | JNJ | Edge |
|---|---|---|---|
| Price as of 2026-08-07 close | $103.12 | $259.24 | |
| Market cap as of 2026-08-10 | $12.2B | $624.7B | |
| P/E as of 2026-08-10 | 29.57 | 29.70 | HALO lower |
| PEG as of 2026-08-10 | 0.94 | 3.39 | HALO lower |
| Net margin as of 2026-08-10 | +24.9% | +21.5% | HALO higher |
| Gross margin as of 2026-08-10 | +82.4% | +68.0% | HALO higher |
| Operating margin as of 2026-08-10 | +35.6% | +25.7% | HALO higher |
| ROE as of 2026-08-10 | +180.6% | +25.7% | HALO higher |
| ROA as of 2026-08-10 | +16.6% | +10.6% | HALO higher |
| Debt / equity as of 2026-08-10 | 14.95 | 0.58 | JNJ lower |
| Revenue growth (YoY) as of 2026-08-10 | +41.1% | +8.1% | HALO higher |
| Revenue CAGR (3y) SEC XBRL | +28.4% | +6.2% | HALO higher |
| Dividend yield as of 2026-08-10 | n/a | +2.1% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-10 | 0.90 | 0.20 | |
| 1-year return as of 2026-08-07 close | +66.1% | +51.1% | HALO higher |
Fundamentals: market data, as of 2026-08-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-07.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.